Profile data is unavailable for this security.
About the company
Celcuity Inc. is a clinical-stage biotechnology company, which develops targeted therapies for the treatment of multiple solid tumor indications. Its lead therapeutic candidate is gedatolisib, a potent, small-molecule reversible inhibitor that selectively targets all Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2. Its development programs for gedatolisib focus on the treatment of patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), or HR+/HER2-, advanced or metastatic breast cancer and patients with metastatic castration resistant prostate cancer. A Phase III clinical trial of VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast has commenced. Its CELsignia companion diagnostic platform is able to analyze live patient tumor cells.
- Revenue in USD (TTM)0.00
- Net income in USD-162.72m
- Incorporated2017
- Employees87.00
- LocationCelcuity Inc16305 36th Ave N Ste 100MINNEAPOLIS 55446-4285United StatesUSA
- Phone+1 (302) 658-7581
- Fax+1 (302) 655-5049
- Websitehttps://www.celcuity.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ACADIA Pharmaceuticals Inc | 1.07bn | 391.00m | 3.84bn | 796.00 | 9.87 | 3.12 | 9.52 | 3.58 | 2.28 | 2.28 | 6.31 | 7.21 | 0.7787 | 3.14 | 9.73 | 1,346,112.00 | 28.42 | 3.92 | 37.60 | 5.17 | 91.69 | 93.59 | 36.49 | 4.59 | 3.71 | -- | 0.00 | 0.00 | 11.87 | 19.39 | 72.66 | -- | 68.65 | -- |
| Gyroscope Therapeutics Holdings Ltd(ADR) | -100.00bn | -100.00bn | 3.93bn | 167.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -70.87 | -- | -58.56 | -- | -- | -- |
| Crinetics Pharmaceuticals Inc | 7.70m | -465.32m | 4.20bn | 594.00 | -- | 3.87 | -- | 545.84 | -4.94 | -4.94 | 0.0818 | 10.38 | 0.006 | -- | 1.71 | 12,956.23 | -36.34 | -36.26 | -38.52 | -38.45 | 66.07 | -- | -6,046.22 | -6,696.84 | 12.30 | -- | 0.00 | -- | 640.71 | 155.27 | -55.93 | -- | 98.71 | -- |
| Erasca Inc | 0.00 | -127.69m | 4.37bn | 103.00 | -- | 11.50 | -- | -- | -0.4506 | -0.4506 | 0.00 | 1.23 | 0.00 | -- | -- | 0.00 | -26.90 | -41.53 | -28.68 | -44.78 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -29.28 | -- | -36.84 | -- |
| Terns Pharmaceuticals Inc | 0.00 | -94.44m | 4.41bn | 59.00 | -- | 12.79 | -- | -- | -1.03 | -1.03 | 0.00 | 3.25 | 0.00 | -- | -- | 0.00 | -27.78 | -32.69 | -28.92 | -35.03 | -- | -- | -- | -33,013.70 | -- | -- | 0.00 | -- | -- | -- | 1.50 | -- | -45.82 | -- |
| Structure Therapeutics Inc (ADR) | 0.00 | -141.20m | 4.47bn | 220.00 | -- | 2.94 | -- | -- | -2.49 | -2.49 | 0.00 | 21.41 | 0.00 | -- | -- | 0.00 | -11.35 | -18.40 | -11.83 | -19.33 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -15.24 | -- | 185.66 | -- |
| Amicus Therapeutics, Inc. | 634.21m | -27.11m | 4.50bn | 511.00 | -- | 16.25 | -- | 7.10 | -0.0885 | -0.0885 | 2.05 | 0.8822 | 0.7311 | 0.4196 | 5.86 | 1,241,116.00 | -3.13 | -17.56 | -4.02 | -21.71 | 88.50 | 89.24 | -4.27 | -32.86 | 1.88 | 0.8051 | 0.5888 | -- | 20.05 | 19.44 | 51.68 | -- | 0.424 | -- |
| Scholar Rock Holding Corp | 0.00 | -353.43m | 4.52bn | 196.00 | -- | 17.94 | -- | -- | -3.15 | -3.15 | 0.00 | 2.47 | 0.00 | -- | -- | 0.00 | -119.63 | -45.06 | -144.40 | -51.62 | -- | -- | -- | -1,134.62 | -- | -- | 0.2891 | -- | -- | -- | -48.56 | -- | -49.93 | -- |
| Apogee Therapeutics Inc | 0.00 | -253.67m | 4.76bn | 196.00 | -- | 6.93 | -- | -- | -4.36 | -4.36 | 0.00 | 9.89 | 0.00 | -- | -- | 0.00 | -36.18 | -- | -37.98 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -116.88 | -- | -- | -- |
| Alkermes Plc | 1.48bn | 241.66m | 4.87bn | 2.05k | 20.38 | 2.66 | 17.83 | 3.30 | 1.43 | 1.43 | 8.74 | 10.99 | 0.6498 | 1.04 | 4.08 | 719,950.80 | 10.64 | 10.11 | 13.68 | 13.22 | 86.69 | 84.10 | 16.37 | 15.06 | 3.19 | -- | 0.00 | 0.00 | -5.25 | 7.28 | -35.06 | -- | -0.8671 | -- |
| Celcuity Inc | 0.00 | -162.72m | 4.97bn | 87.00 | -- | 39.74 | -- | -- | -3.67 | -3.67 | 0.00 | 2.70 | 0.00 | -- | -- | 0.00 | -43.45 | -42.61 | -47.58 | -45.75 | -- | -- | -- | -- | -- | -48.30 | 0.7325 | -- | -- | -- | -75.26 | -- | -8.05 | -- |
| CG Oncology Inc | 4.04m | -161.00m | 5.11bn | 142.00 | -- | 6.49 | -- | 1,265.48 | -2.08 | -2.08 | 0.0523 | 9.33 | 0.0052 | -- | 5.50 | 28,450.71 | -20.82 | -- | -21.55 | -- | -16.31 | -- | -3,985.03 | -- | 24.58 | -- | 0.004 | -- | 254.70 | -- | -82.87 | -- | -- | -- |
| Immunovant Inc | 0.00 | -464.20m | 5.44bn | 362.00 | -- | 5.51 | -- | -- | -2.68 | -2.68 | 0.00 | 4.85 | 0.00 | -- | -- | 0.00 | -63.01 | -47.00 | -69.35 | -51.13 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -59.58 | -- | 89.57 | -- |
| Protagonist Therapeutics Inc | 46.02m | -130.15m | 5.83bn | 132.00 | -- | 9.29 | -- | 126.60 | -2.04 | -2.04 | 0.7239 | 9.82 | 0.0651 | -- | 12.10 | 348,606.10 | -18.42 | -8.51 | -19.72 | -9.31 | -- | -- | -282.83 | -31.44 | -- | -- | 0.00 | -- | -89.41 | 9.96 | -147.29 | -- | 27.55 | -- |
| Cogent Biosciences Inc | 0.00 | -277.80m | 6.04bn | 258.00 | -- | 10.96 | -- | -- | -2.15 | -2.15 | 0.00 | 3.95 | 0.00 | -- | -- | 0.00 | -51.99 | -55.96 | -57.41 | -62.16 | -- | -- | -- | -- | -- | -- | 0.2594 | -- | -- | -- | -37.96 | -- | -- | -- |
Data as of Mar 03 2026. Currency figures normalised to Celcuity Inc's reporting currency: US Dollar USD
55.10%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Baker Bros. Advisors LPas of 31 Dec 2025 | 7.92m | 17.11% |
| Perceptive Advisors LLCas of 31 Dec 2025 | 3.16m | 6.83% |
| Avoro Capital Advisor LLCas of 31 Dec 2025 | 3.11m | 6.72% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 2.24m | 4.85% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 2.00m | 4.33% |
| Soleus Capital Management LP (Investment Management)as of 31 Dec 2025 | 1.81m | 3.91% |
| SSgA Funds Management, Inc.as of 31 Dec 2025 | 1.64m | 3.54% |
| Morgan Stanley & Co. LLCas of 31 Dec 2025 | 1.36m | 2.94% |
| T. Rowe Price Associates, Inc. (IM)as of 31 Dec 2025 | 1.21m | 2.61% |
| Tang Capital Management LLCas of 31 Dec 2025 | 1.05m | 2.27% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
